NEUROCRINE BIOSCIENCES INC Marketable Securities, Unrealized Gain (Loss)
NEUROCRINE BIOSCIENCES INC (NBIX) reported Marketable Securities, Unrealized Gain (Loss) of -$3.50 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-11.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2022-02-11
- NEUROCRINE BIOSCIENCES INC marketable securities, unrealized gain (loss) for fiscal 2021 was -$3.50M, a 975.00% decline from fiscal 2020.
- NEUROCRINE BIOSCIENCES INC marketable securities, unrealized gain (loss) for fiscal 2020 was $400.00K, a 88.24% decline from fiscal 2019.
- NEUROCRINE BIOSCIENCES INC marketable securities, unrealized gain (loss) for fiscal 2019 was $3.40M.
- NEUROCRINE BIOSCIENCES INC marketable securities, unrealized gain (loss) for fiscal 2018 was -$100.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 12 month | Marketable Securities, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|
| 2021-12-31 | -$3.50M 10-K · filed 2022-02-11 | |
| 2020-12-31 | $400.00K 10-K · filed 2022-02-11 | |
| 2019-12-31 | $3.40M 10-K · filed 2022-02-11 | $3.35M 10-K · filed 2020-02-07 |
| 2018-12-31 | -$100.00K 10-K · filed 2021-02-05 | -$82.00K 10-K · filed 2020-02-07 |
| 2017-12-31 | -$1.53M 10-K · filed 2020-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |